EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients

Rui Su, Lihua Yan, Bei Jiang, Jia Li, Ping Li, Yonggang Liu, Jing Miao, Cuiying Chen, Liang Xu, Li Ren, Yuqiang Mi iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Rui Su und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Precision Instruments and Opto-Electronics Engineering, Tianjin University, Tianjin, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Polysaccharides, Biomarkers, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin Municipality, Tianjin Health Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to establish a novel noninvasive model based on the serum N‐glycan spectrum for providing an objective value for determining the stage of liver necroinflammation related to chronic hepatitis B (CHB) patients. N‐glycan profiles of the sera of 295 treatment‐naïve CHB patients were analyzed. N‐glycan profiles were tested for different liver necroinflammation stages using DNA sequence‐assisted fluorophore‐assisted carbohydrate electrophoresis. A serum N‐glycan model named N‐glycan‐LI (NGLI) using support vector machine was selected to evaluate the classification of liver necroinflammation (G < 2 and G ≥ 2). The area under the receiver operating characteristic curves (AUROCs) was 0.898 (training set, n = 236) and 0.911 (validation set, n = 59) regardless of the stage of liver fibrosis (AUROC = 0.886 and 0.926, respectively, in S < 2 and S ≥ 2 group). The NGLI correspondingly had the highest specificity (SP) of 90.79% and negative predictive value of 92.00% in an inactive stage (including immune‐tolerant [IT] and inactive‐carrier [IC] stage), had the highest positive predictive value of 95.18% in stage immune‐active, and had the highest SP of 93.94% in grey zone IT + IC. N‐glycan profiles appear to correlate well with hepatic necroinflammation in CHB when compared with liver biopsy. The newly developed model appears to reliably predict liver damage in naïve‐treatment patients with CHB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicPolysaccharidesBiomarkersLiverHumansMaleFemaleAdultMiddle AgedROC CurveNecrosisYoung AdultInflammationLiver CirrhosisSensitivity and Specificity

Stichwörter der Autor:innen

N‐glycanchronic hepatitis Bdiagnostic performancemachine learningnecroinflammationtreatment‐naïve

Substanzen

PolysaccharidesBiomarkers

Autor:innen und Institutionen

  • School of Precision Instruments and Opto-Electronics Engineering, Tianjin University, Tianjin, China.
  • Tianjin Institute of Heptology, Tianjin Second People's Hospital, Tianjin, China.
  • Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Department of Research and Development, Sysdiagno (Nanjing) Biotech Co. Ltd, Nanjing, Jiangsu Province, China.
  • National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China.

ORCID-Profile: Yuqiang Mi

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Tianjin Municipality
  • Tianjin Health Science and Technology Project
  • Tianjin Health Science and Technology Project key discipline special
  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • Research project in key areas of TCM in 2024

Zitieren

APA

Su, R., Yan, L., Jiang, B., Li, J., Li, P., Liu, Y., Miao, J., Chen, C., Xu, L., Ren, L., & Mi, Y. (2024). A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients. Journal of Medical Virology. https://doi.org/10.1002/jmv.29863

Vancouver

Su R, Yan L, Jiang B, Li J, Li P, Liu Y, et al. A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients. Journal of Medical Virology. 2024. doi:10.1002/jmv.29863

BibTeX
@article{Su2024,
  author = {Su, Rui and Yan, Lihua and Jiang, Bei and Li, Jia and Li, Ping and Liu, Yonggang and Miao, Jing and Chen, Cuiying and Xu, Liang and Ren, Li and Mi, Yuqiang},
  title = {A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29863}
}
Kostenlos starten →